Study Looking at Safety of Dacomitinib and How it Works in the Body in People with Livers that Do Not Work Properly

A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Plasma Pharmacokinetics and Safety of Dacomitinib in Participants With Severely Impaired Hepatic Function Relative to Participants With Normal Hepatic Function

Category & Conditions: Cancer

Medicine: VIZIMPRO® TABLETS(DACOMITINIB)

ClinicalTrials.gov Identifier (NCT): NCT03865446

Protocol ID: A7471058

Print Download

Open Plain Language Summary Result: Click here